Skip to content

Press Releases

June 24, 2024

Panbela Therapeutics Announces Third Independent Safety Review of Phase 3 ASPIRE Clinical Trial

DSMB Recommended Continuation with No Trial Modification

  • DSMB Recommends Continuation without Modification for Third Time
  • Safety Review Included 395 Patients
  • Interim Survival Analysis Still Expected Early 2025 given Lower-Than-Expected Event Rate
  • Low Event Rate Suggests Potential for Prolonged Survival
  • Rapid Enrollment Positions Company for Enrollment Completion by Q1 2025; Earlier Than Expected
View/download press release »

Sign up to receive press releases via email